Cargando…

Trends in clinical development of pediatric cancer for PD-1 and PD-L1 inhibitors: an analysis of ClinicalTrials.gov

Compared with cytotoxic chemotherapy, radiotherapy, and surgery, positive findings have been acquired through the approach of blocking the programmed cell death protein 1 (PD-1) pathway with antibodies that exert inhibitory effects on PD-1 or cell death protein ligand 1 (PD-L1). Results from clinica...

Descripción completa

Detalles Bibliográficos
Autores principales: Que, Yi, Hu, Yang, Hong, Dongchun, Zhang, Yizhuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8479973/
https://www.ncbi.nlm.nih.gov/pubmed/34583971
http://dx.doi.org/10.1136/jitc-2021-002920
_version_ 1784576375345119232
author Que, Yi
Hu, Yang
Hong, Dongchun
Zhang, Yizhuo
author_facet Que, Yi
Hu, Yang
Hong, Dongchun
Zhang, Yizhuo
author_sort Que, Yi
collection PubMed
description Compared with cytotoxic chemotherapy, radiotherapy, and surgery, positive findings have been acquired through the approach of blocking the programmed cell death protein 1 (PD-1) pathway with antibodies that exert inhibitory effects on PD-1 or cell death protein ligand 1 (PD-L1). Results from clinical trials showed great potential in adult patients with cancers, such as melanoma, non-small cell carcinoma, and nasopharyngeal carcinoma. However, studies of checkpoint inhibitors specifically targeting PD-1/PD-L1 in pediatric patients are limited. We evaluated ongoing clinical trials using PD-1 or PD-L1 inhibitors alone or in combination with other therapies to treat pediatric cancer. The proportion of PD-1/PD-L1 combination clinical trials has increased since 2018; the three most common trials over the past 2 years used CTLA-4 monoclonal antibodies, chemotherapy, and therapies that target the vascular endothelial growth factor axis. This commentary aimed to provide trends and specific insights into methods for conducting clinical trials of immunotherapy in the pediatric population.
format Online
Article
Text
id pubmed-8479973
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-84799732021-10-08 Trends in clinical development of pediatric cancer for PD-1 and PD-L1 inhibitors: an analysis of ClinicalTrials.gov Que, Yi Hu, Yang Hong, Dongchun Zhang, Yizhuo J Immunother Cancer Commentary Compared with cytotoxic chemotherapy, radiotherapy, and surgery, positive findings have been acquired through the approach of blocking the programmed cell death protein 1 (PD-1) pathway with antibodies that exert inhibitory effects on PD-1 or cell death protein ligand 1 (PD-L1). Results from clinical trials showed great potential in adult patients with cancers, such as melanoma, non-small cell carcinoma, and nasopharyngeal carcinoma. However, studies of checkpoint inhibitors specifically targeting PD-1/PD-L1 in pediatric patients are limited. We evaluated ongoing clinical trials using PD-1 or PD-L1 inhibitors alone or in combination with other therapies to treat pediatric cancer. The proportion of PD-1/PD-L1 combination clinical trials has increased since 2018; the three most common trials over the past 2 years used CTLA-4 monoclonal antibodies, chemotherapy, and therapies that target the vascular endothelial growth factor axis. This commentary aimed to provide trends and specific insights into methods for conducting clinical trials of immunotherapy in the pediatric population. BMJ Publishing Group 2021-09-28 /pmc/articles/PMC8479973/ /pubmed/34583971 http://dx.doi.org/10.1136/jitc-2021-002920 Text en © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See https://creativecommons.org/licenses/by/4.0/.
spellingShingle Commentary
Que, Yi
Hu, Yang
Hong, Dongchun
Zhang, Yizhuo
Trends in clinical development of pediatric cancer for PD-1 and PD-L1 inhibitors: an analysis of ClinicalTrials.gov
title Trends in clinical development of pediatric cancer for PD-1 and PD-L1 inhibitors: an analysis of ClinicalTrials.gov
title_full Trends in clinical development of pediatric cancer for PD-1 and PD-L1 inhibitors: an analysis of ClinicalTrials.gov
title_fullStr Trends in clinical development of pediatric cancer for PD-1 and PD-L1 inhibitors: an analysis of ClinicalTrials.gov
title_full_unstemmed Trends in clinical development of pediatric cancer for PD-1 and PD-L1 inhibitors: an analysis of ClinicalTrials.gov
title_short Trends in clinical development of pediatric cancer for PD-1 and PD-L1 inhibitors: an analysis of ClinicalTrials.gov
title_sort trends in clinical development of pediatric cancer for pd-1 and pd-l1 inhibitors: an analysis of clinicaltrials.gov
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8479973/
https://www.ncbi.nlm.nih.gov/pubmed/34583971
http://dx.doi.org/10.1136/jitc-2021-002920
work_keys_str_mv AT queyi trendsinclinicaldevelopmentofpediatriccancerforpd1andpdl1inhibitorsananalysisofclinicaltrialsgov
AT huyang trendsinclinicaldevelopmentofpediatriccancerforpd1andpdl1inhibitorsananalysisofclinicaltrialsgov
AT hongdongchun trendsinclinicaldevelopmentofpediatriccancerforpd1andpdl1inhibitorsananalysisofclinicaltrialsgov
AT zhangyizhuo trendsinclinicaldevelopmentofpediatriccancerforpd1andpdl1inhibitorsananalysisofclinicaltrialsgov